Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020)

Historic Asset Writedowns and Impairment for Rocket Pharmaceuticals (RCKT) over the last 2 years, with Q2 2020 value amounting to -$1000.0.

  • Rocket Pharmaceuticals' Asset Writedowns and Impairment changed N/A to -$1000.0 in Q2 2020 from the same period last year, while for Dec 2023 it was -$1000.0, marking a year-over-year decrease of 10161.29%. This contributed to the annual value of $574000.0 for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q2 2020, Rocket Pharmaceuticals' Asset Writedowns and Impairment is -$1000.0.
  • In the past 5 years, Rocket Pharmaceuticals' Asset Writedowns and Impairment ranged from a high of $63000.0 in Q1 2020 and a low of -$1000.0 during Q2 2020